These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 24756800

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW, Jabbour E, Kantarjian HM, Giles FJ.
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [Abstract] [Full Text] [Related]

  • 4. Decitabine in myelodysplastic syndromes.
    Saba HI, Wijermans PW.
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [Abstract] [Full Text] [Related]

  • 5. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA, Talwar S, Yang AS.
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR.
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [Abstract] [Full Text] [Related]

  • 10. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A, Santini V.
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [Abstract] [Full Text] [Related]

  • 11. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Claus R, Almstedt M, Lübbert M.
    Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG, Nagler A.
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [Abstract] [Full Text] [Related]

  • 15. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
    Fenaux P.
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L, Greil R.
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [Abstract] [Full Text] [Related]

  • 18. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS.
    Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.